Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
i talk to schwab portfolio manager yesterday he told me a lot of peoples that he know buying AVXL lately as well .HAPPY 4TH LOOOONGS.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS
About the only trading going on today is between games of Candy Crush
by the Jr. floor trader stuck with working until the close.
Happy 4th in the US and Good Luck with La Pen in EU.
I just don’t agree with your view on LPC! And you posted a dubious reference of sort you rightly lambast others for.
If you carefully read the LPC agreement you will see there is nothing vulturous about it that can harm shareholders other than what one might expect from raising capital for a risky business.
Perhaps this definition suits the conversation.....
Thirds of a year are 122 days (aprox).
The middle third of the year would then be
May 2 through September 1.
Worth any more discussion or must we do 1/5, 1/7, 1/9, etc. to satisfy the definition?
We could break it down into seconds or smaller and use an atomic clock if
you believe that is necessary.
As usual, Missling is vague in his commitment(s).
Nonsense. The terms of the agreement are what characterize the quality of the ATM funding, not some label applied to the ATM provider.
LPC offers a Service at a price.
Do they HOLD shares used as payment for the service? Generally, NO.
Is that a Negative? Personal judgement.
Are there other avenues to suit Anavex funding? YES.
Has Missling chosen to use them? Seemingly NO.
Would Missling use them if the "costs" were less? Likely.
Do others have access to cheaper financing? Most assuredly YES.
Now, characterize all you want on either side of the definition.
Wasted effort if not in the position to affect choice.
So what? It doesn’t change the facts as described in detail in the article.
Missling uses LPC because he can’t raise money from serious, top-tier, influential investors who have big bucks and lots of sector expertise, who can help companies become successful in myriad ways. Also, serious investors want visibility, honesty, performance, and accountability. This is antithetical to Missling. He does not want pesky investors breathing down his neck and questioning what he’s doing. This is an undeniable fact based on a great deal of real-world evidence.
Although you gave up WGT status a while ago, you love to take potshots at me whenever you can. That’s OK with me but it doesn’t speak well for you.
Thanks very much falconer! Your input is always greatly valued and appreciated.
jmvho
Agree. AVXL June Presentation has just changed the upcoming PD trial to >6 month. It would be interesting to see if FDA also ask AVXL to used Part II as primary endpoint as oppose to planned II+III. The other co-primary CGI-I looks solid based on updated AD p2b/3 TLD. Both companies struggle with how to find the sweet spot (patients not too far in the disease progression that drug not effective but also not too early that blows up the co-primary behavioral endpoint). It’s frustrating that Maria can say we will present data to FDA in the fall while it seems that AVXL never talks to FDA.
The two endpoints, MDS-UPDRS Part II + III and Clinical Global Impression – Improvement (CGI-I) measured in this study are the planned primary and key secondary endpoints in Anavex’s forthcoming pivotal 6-month Parkinson’s disease study.
From your link!
WHY UTOPIA CAPITAL RESEARCH
We are a membership community of activist short sellers and veteran traders, some of whom have been active since the 1990s
Wrong! LPC is a vulture investor and a notorious one at that: https://utopiacap.com/lincoln-park-capital/
I'm Not Impressed
Curious if you have looked at Annovis's buntanetap drug for Parkinson's, it's MOA, and what level of competition, if any, it might pose for Anavex in PD or AD ?
You have your opinion which I do not share.
To use your analogy, the can will stop rolling in the next 6 to 9 months.
We shall see.
Financially there is nothing to worry about with the LPC agreement for raising cash - the vulture bit is oversold. The key downside, or advantage depending on perspective, is that there are few but growing a bit strategic institutional investors helping to stabilise volatility. That could change based on what we hear 28th July, provided it is solid and underpins the idea that an MAA filing could be succesful in gaining EMA approval from current AD clinical trials data.
In case anyone is wondering...."Yes, we are on the point". AND, it's time to act that way.
Our first task is to define a better(real) path for the FDA and others who are clearly struggling as they look for a definition of , "How to recognize CNS diseases treatment efficacy". Also known as , " The problem statement", known to some as, "what's not working". .
FDA have run out of RUNWAY and they have no place to hide. ...IMO, AVXL will have to ACT LIKE THEY ARE LEADING. Perhaps EMA can help w/that...ASAP.
falconer66a - Curious if you have looked at Annovis's buntanetap drug for Parkinson's, it's MOA, and what level of competition, if any, it might pose for Anavex in PD or AD ?
Thanks in advance,
jmvho
I worked for a multi-billion dollar company. Some of the people at the top are not that sharp. Like an inbred club. Missling is no different, He is not the worst CEO those CEOs end up in prison. Other CEO walk off with millions of dollars after burning the company to the ground. Plenty of these loser CEOs'. Golden parachutes are like peeing on the stockholders after the CEO sucks the life out of the company for a couple of years, Plenty of CEOs suck bigtime MIssling is not there yet.
“Nor is my objective to deter buying in AVXL”
5,000 Biochecker4 posts clearly read otherwise.
Almost like asking someone not to believe what they just witnessed in a debate performance.
FWIW—ANVS results-
Adam Feuerstein
@adamteuerstein
Follow
$ANVS CEO Maria Maccecchini, on a call last night, admitted the failure of its buntanetap Parkinson's study:
The primary endpoint was MDS-UPDRS Part Il in the ITT population n=523
Maria: "This is the ITT population before subdividing them into the groups. And if you look at MDS-UPDRS Part II, you see that it pretty much doesn't move. The total ITT population does not change at all in MDS-UPDRS Part I!."
MDS-UPDRS Part Ill is the most important secondary endpoint. It also failed.
Maria: "Now, the MDS-UPDRS Part Ill part in the ITT population looks pretty much identical to the ITT population in our Alzheimer patients, everybody improves because that's what we see. We had high placebo, we had good response. Minus 3 is excellent response, but the placebo also has minus 3."And below is the Annovis graph showing the failure. Lowered scores in MDS-UPDRS means improvement. Placebo performed better than butanetap.
This is why Annovis is falsely touting a win on a small subgroup of study participants with a Parkinson's diagnosis of greater than 3 years. The analysis is invalid and will be laughed out of the FDA if the company tries to file on it, but that's a story for another time.
You are correct about the ATM agreement. When the deal with LPC was first disclosed I compared the LPC agreement and Cantor’s prior agreement. LPC’s had slightly better terms, although I don’t recall why now. And Cantor is hardly a “vulture investor”. It’s a superficial and inaccurate term being used by fudsters, as usual.
I agree Missling hasn’t failed. The reason is that he never lets things get to the point of failure. As Kund correctly states, his strategy is to kick the can down the road basically forever. If you look at it dispassionately, it’s pretty obviously true.
I said nothing of the kind nor is my objective to deter buying in AVXL. I simply stated that getting family and friends involved in a speculative stock is a recipe for damaging your most valued relationships. I’ve seen it happen to people I know. Your family and friends can make their own investment decisions without help.
If your relationships with family members and friends need shoring up, getting them involved in a speculative stock, even if you believe it’s going to be a big winner, isn’t the way to do it. Nurture your relationships with kindness, no speculative stocks.
If someone is shown Anavex, does their own due diligence, and decides to put some money to work, I have no problem with that.
Have a nice 4th. Don’t drink too much Kool aid.
Annovis management is being very aggressive with NDA plans for PD, though they do acknowledge it's a long shot at this stage. The biggest concern is the complete reliance on (ad hoc, apparently) subgrouping, since the ITT population didn't show any potential signal. Company has contingency plans if the FDA balks, which it likely will. I suspect they'll need not just extension data, but a new revised phase 3.
I wholeheartedly agree Steady, the naysayers are FUDsters and purposely fail to acknowledge the positives and relentlessly push a negative bias. If they weren’t shorting the stock or providing some kind of cover to help maintain a lower share price, they simply wouldn’t be here on this message board.
It might be that CEO problem many believe Anavex have or it may be that neither ANVS or AVXL have what it takes to file an NDA for Parkinson's yet, but ANVS is trying perhaps in vain.
EU approves Sanofi's Dupixent for 'smoker's lungs' July 3 (Reuters) - Sanofi (SASY.PA), opens new tab and partner Regeneron (REGN.O), opens new tab on Wednesday won European Union approval for wider use of their Dupixent injection in patients with a chronic lung disease, a rare case of the EU clearing a drug faster than the United States.
Reading the first line:
https://www.reuters.com/business/healthcare-pharmaceuticals/eu-approves-sanofis-dupixent-smokers-lungs-2024-07-03/
That’s the name of the game right?
Deter any potential new investors from purchasing.
Suggesting it’s a bad stock, yet it’ll 100% hit $8 before $1.
Making it an easy double and beyond
You keep using that term "vulture investor" yet the terms that Mislsing has arranged are as you said an ATM.
The terms of the ATM deal are not toxic financing, there is no convertible debt, none of the death spiral clauses involved. The ATM can be used at Anavex's choosing or not as circumstances require.
Again the terminology you are using conveys an incorrect presentation of the facts.
Missling has managed Anavex to a critical point with moderate share count and no debt. If you look around at some of the other biotechs some have 1.2 billion shares outstanding like NWBO. Others are short of cash like ANVS. Some are one drug and one indication companies.
Keep attacking the guy if you must, Mr. know it all, but the only person you are fooling is yourself.
We shall see who is fooling whom, when the dust settles.
Our honest day will come but not by way of Anvs style. Imo Annovis has just made another deal with the devil. Thats the merry go round you are limited too when you dont have a financial background like Dr. Missling. Good data or no data the price still gets squeezed all the same making hard moves down and up on BS pr’s. This is the game, the transfer of wealth from the rich to he richer. The ink probably is still wet from the deal on the latest round of financing we will hear about in the next week or so to fill the coughers for the next trial. They have to “cycle” the shares out some how so the “always fair and balanced market” kicks up the HFT machines sending out a call to all the pirahna traders for a feeding frenzy.
Good for those that got in and out, many arent so lucky and get caught in the cycle and suffer a long slow death much like many of the naysayers here.
Wash, rinse, repeat.
Be careful with your praise of ANVS. Your cubicle mate might have been assigned to bash it. It could get awkward around the water cooler.
Can someone explain why ANVS plan to ask for an NDA (ANVX p3 Parkinson conference call ) with 6 point UPDRS total score improvement on a post-hoc subgroup (MH>3yr) while AVXL sits on 14.5 point UPDRS total score improvement for the past 2 years?
ANVS has 11 million outstanding shares. They can sell 30-40 million shares for $3-4 each and raise $100-120 million. What has AVXL done? The same thing, but slowly. In 10 years, the share count has gone up from 25 million to 80 million. If you count the reverse split, the share count has gone to 320 million.
ANVS will come out ahead of this POS. Their CEO is aggressive and means business, unlike the clown who is stuck in buzzwords, with no action—just play and pay.
This last sentence looks like an invitation to ANAVEX to file NDA pronto. The MAB they approved today is anything but safe.
"FDA Roundup: July 2, 2024
. Today’s approval is evidence of the FDA’s commitment to helping more safe and effective drugs to treat Alzheimer’s disease become available."
As to the RETT trials. The RETT caregivers parents etc are a very tight community. They all have their own media sources to get together. My daughter hasn't had a seizure in well over a month. My daughter climbed the stairs to the 2nd floor bedroom that is a FIRST EVER. My Daughter gets dizzy spell after her daily dose. My daughter has no dizzy spells and continues to have seizures the same as before getting into this trial. She must be on Placebo. Or a parent sees something that just might be an improvement and they broadcast that to all the others. In short order that trial was the same as an open label trial.
Someplace and I don't remember which trial it was in... Anavex said if they gave the pill / dose at bedtime the patient didn't have dizzy spells and actually slept better.
to Plex your question re: "Steady" he is one of our moderators. His first post to AVXL on ihub was 07/27/2016 04:47:19 PM. He replied to something Frol had commented about. Perhaps he like some of the rest of us migrated here from other boards... Yahoo etc.
John k9uwa
“Now that I've bought some stock for me, I better call my family and friends....”
If you value your family relationships and friendships, don’t risk it by dragging them into a speculative penny stock like Anavex. I’ve known people who’ve done this and it usually works out badly. Just ask bs2020.
I am speaking from professional experience dealing with CEOs and other senior executives in an organizational consulting capacity for more than two decades. In my professional career, I have encountered all types of senior execs but never have I seen a CEO as singularly awful as Missling. On every objective level, the guy is a disaster. As for managing the finances well, any idiot can raise money through a vulture investor. It doesn’t take any financial acumen to sign ATM deals. Actually attracting real investors who have the financial clout, reputation, and ability to help build successful companies does take financial acumen. Missling uses a vulture investor because 1) he does not have financial acumen, and 2) because he does not have to answer to serious investors who would demand excellent performance and accountability, or else.
Keep defending the guy if you must, Mr. know It All, but know that the only person you’re fooling is yourself.
I just watched this '60 Minutes' on Dementia, Alzheimer, Aging and more. Is worth the watch IMO. It is a follow up 2014 testing and interviews looking for changes up to the present; in particular people over 90.
Not only have you been lying to everybody for a decade and making the worst predictions anyone's ever seen but now you're going to tell other people on the board what they can and can't do who the heck are you disappear for a while do us all a favor
Correct. Missling has little relevance to whether the drug gets approved or not. It’s nothing more than a talking point that they’ve decided to latch onto.
Deal, or no deal. Your choice.
Steady_T,
STOP DISCUSSING AVXL with bashers, FUDsters and/or shorters!!!
GOD bless,
Xena...I was talking to you through what I remembered...Not you saying those things but Kund and the like ilk, like OB or someone like that.
Please support this statement with fact... It does not seem correct to me and I am the one you are allegedly quoting....
If you go back a few years in your thinking Xena, it was; "No patent protection and their funding sources were wrong!"
The problem is, with modern living situations (urban, rural, economic situation,chemical exposure... etc.. etc...
It isn't possible to define "normal aging".
LOL I wonder what you would say if CM let cash dwindle to $3m, delivered a failed AD trial and then an equivocal PD trial. ANVS can do it, I think, but they are going to have to raise $150m-$250m and run another, larger PD P3. They have ~$100m market cap so that will be a lot of (worthwhile) dilution.
Interesting...Area 51 Locality has been busy...https://globe.adsbexchange.com/?icao=a2b320,a3685d,adce1a&lat=36.582&lon=-116.054&zoom=7.5&showTrace=2024-07-02×tamp=1719962983
10 years after published paper release
Quote: "Once the 2-73 MOA is proven they will all take notice."
That day is coming - within the next 5 months - when the NDA is filed and the peer-reviewed journal is announced. THAT will not only confirm the MOA of A2-73, but it will send a message throughout the biotech sector that Anavex is for real.
And make no mistake, BP will be knocking on our door wanting to partner in every which way they can. Why? Because we have just filed our NDA...and everyone knows that that is the final step before approval is granted.
The clock starts ticking in everyone's head...and they start asking themselves: Does Anavex really have enough data to be approved for an NDA? Oh wait! I better read that peer-reviewed article again. Holy smoke. I had no idea that A2-73 was this effective in preventing brain atrophy...and look at all of the benefits of autophagy! This drug is incredible. I better buy some stock before it breaks the $100 mark.
Now that I've bought some stock for me, I better call my family and friends...because if their NDA is approved, the stock could easily break $300/share.
Of course, this is just my opinion but I'm betting that this scenario plays out exactly as I've said.
Cheers!
Very good data from the adult Rett trial?
No that Avatar Rett trial should have told Anavex to not go with a 2:1 dose:placebo design!
LOL!!!
So if Missling had said first half of 2024 you would have marginal excuse to gripe...
But "mid-2024" is a generalized term that could apply to months or weeks either side of the date that marks "mid-2027"
What is the middle day of the year 2024?
This is the latest accepted revision, reviewed on 2 July 2024. July 2 is the 183rd day of the year (184th in leap years) in the Gregorian calendar; 182 days remain until the end of the year. In common years, this date marks the midpoint of the year, as 182 days both proceed and follow it in the Gregorian calendar.
July 2 - Wikipedia
Wikipedia
https://en.wikipedia.org › wiki › July_2
That outcome was unexpected due to the very good data from the Adult Rett trials and the expectation that treating Rett patients earlier in the disease process would yield even better results.
Wasn't the improvement in RSBQ better than that of Trofinetide P3?
Followers
|
1075
|
Posters
|
|
Posts (Today)
|
29
|
Posts (Total)
|
463263
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |